Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 14/20 | 0.39 |
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23892623 | 1.00 | EPHA2 (0.39) | EPHA2KDREPHB4ERBB2PRMT5 | |
| SCHEMBL23892508 | 0.92 | EPHA2 (0.40) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL25955833 | 0.85 | SRC (0.40) | EPHA2KDRERBB2EGFR | |
| SCHEMBL23892689 | 0.85 | SRC (0.41) | ERBB2PRMT5WDR77METTL3EGFR | |
| SCHEMBL23892344 | 0.85 | PRMT5 (0.48) | PRMT5WDR77METTL3 | |
| SCHEMBL23892565 | 0.85 | PRMT5 (0.48) | PRMT5WDR77METTL3 | |
| SCHEMBL23892641 | 0.84 | PRMT5 (0.47) | PRMT5WDR77METTL3 | |
| SCHEMBL23892699 | 0.82 | PRMT5 (0.49) | PRMT5WDR77METTL3 | |
| SCHEMBL18571824 | 0.81 | PRMT5 (0.59) | PRMT5WDR77METTL3 | |
| SCHEMBL23892467 | 0.79 | PRMT5 (0.49) | PRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | EPHA2 3912/4885KDR 2294/4885EPHB4 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.